Midas Pharma is actively working on solutions for shortages of pharmaceutical raw materials and disrupted supply chains. By using the Midas’ global network, we identify and establish alternative sources for products with high risk of failure, for example due to dependency on specific territories / limited number of suppliers (see also "Raw material shortages (April 2020)" ). We build on several years’ experience with this strategy, triggered by structural shortages in the industry.
European Fine Chemicals Group (EFCG); Sector group of the European Chemical Industry Council (CEFIC); July 2020
Midas Pharma is contributing to the European Pharmaceutical Strategy in terms of strengthening (domestic) access to essential medicines. Shortages can occur on different levels of the pharmaceutical value chain and require individual solutions. Midas addresses this challenge through formation of a cross-functional team that gathers information on current and potential shortages on precursor, API or finished dosage form level. These information are applied to conduct risk assessments and to generate solutions with the help of Midas’ global network.
A) EU repatriation of FDF, API and Intermediates production
Transfer of technologies to Europe and reactivation of local production: The production of many active ingredients requires up to 10 synthesis steps, with the starting materials and intermediates often coming from only a few non-European sources. It is therefore important not only to focus on the manufacturing and production sites of active ingredients, but to analyze the entire synthesis pathway in order to better identify the reasons for shortages and to be able to take countermeasures. Midas Pharma has the experience and expertise to transfer the production of pharmaceutical precursors, active ingredients and finished products (FDF) to Europe or to reactivate local capacities. Specialized teams of chemists, pharmacists and regulatory experts are available for this purpose.
Midas Pharma is experienced and active in developing sustainable synthesis routes together with European development partners. For example, a more efficient enzyme-catalyzed synthesis has been developed and established, and the intermediate has been marketed already for several years. Similarly, Midas Pharma has initiated the development of an innovative continuous manufacturing process in Europe for an important molecule at significant financial expenditures.
B) Building up safety stocks in Europe
As a consequence of COVID-19 pandemic the call for building up safety stocks becomes stronger as opposed to the "just in time" model that has been popular for years. Due to its drug regulatory approvals and its worldwide network, Midas Pharma is able to assist in building up stockpiles in Germany/Europe, or to expand existing storage capacities.
C) Additional supply chains based on the global network of Midas Pharma
Midas Pharma is experienced in identifying current weaknesses in the supply/production chains of pharmaceutical products and is able to recommend or build alternative supply channels.
D) EU patriation of off-patent innovator drugs
As soon as products become off-patent, the manufacture is often subject to off-shoring, due to changing priorities at the innovator companies. Midas Pharma has developed a concept to counteract this process and to continue domestic production at European contract manufacturers.
If you are also interested in strengthening existing supply chains, present EU-local production capacities or are looking for alternative supply sources of pharmaceutical products / precursors, then we should exchange ideas!
Please do not hesitate to contact us!